A61K 40/434
Leishmania antigens
Official title: {Leishmania antigens}
A61K40/434 (Leishmania antigens) appears on 0 US grants and 3 published applications in this corpus.
Search patents in A61K- Granted patents
- 0
- Published applications
- 3
- Assignees
- 2
- Inventors
- 8
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 2 |
By publication year.
Recent patents
No granted patents in this class yet.
- Cd153 and/or cd30 in infection31 Dec 2020US 2020/0408771 A1The United States of America, as represented by the Secretary, Department of Health and Human Services
- Immunotherapy of solid tumors by vaccination with transgenic leishmania expressing cancer vaccines and with recombinant vaccines with leishmania as adjuvants3 Dec 2020US 2020/0376100 A1Rosalind Franklin Univ. of Medicine and Science
- Method for generating antigen-presenting cells12 Oct 2006US 2006/0228342 A1
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.